array:5 [
  "content-type" => array:1 [
    0 => "text/html; charset=UTF-8"
  ]
  "cache-control" => array:1 [
    0 => "no-cache, private"
  ]
  "date" => array:1 [
    0 => "Mon, 20 Jan 2025 04:08:22 GMT"
  ]
  "set-cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6IjZ2dGYrZDhDeEQwd1dwUFZTbjBDL0E9PSIsInZhbHVlIjoiRkFPQ0txbWdFTUlQdUthZS9RMXBjd2swYnI2KzhDNUlWMHRYdUpsYkdiaWdaRjBJekFTbWZhZTFSaE52SUR5TXJBVW11U2lzRnp3amZkSUtwanNVTjdFOHE3dlhqZUlTQUxlbXQwN0dzZEQ1Y0NvM0NRN01kV3lzbURpVDFpR1AiLCJtYWMiOiJjYzc3ZGQ2YTMzZDE0OGI0NDVmOTk3OGY2OTI1N2E3NzZlMWE4N2FjNWNlODc2YTY3YjI4ZTA1ZWIwYzUxZGNhIiwidGFnIjoiIn0%3D; expires=Tue, 20 Jan 2026 04:08:22 GMT; Max-Age=31536000; path=/; secure; samesite=lax"
    1 => "republica_session=eyJpdiI6InIxODdqTHNlMzNXN29YQXhsRDVzbWc9PSIsInZhbHVlIjoiZW9wMUM5SWpENklYUVJWd1k4Vk5odmpMeFNMcm5mblhQYmNKS1c1d0hDTi9GUm1pbjRONnNicHBDNG4vK0ExTUg3QnJHbXZ0ZkczMTY3dlVabWRpVWtvNEVtMDVqVVRYYkFaeGE1djFkYnc4VVZkN0wyWVdmY0ZnTEJ5UmNOb24iLCJtYWMiOiI4YWY2MGQ0M2FiYjVjZWVmYjliOTZiMTYyNTY4YWUzOTk2ZjkyYzZlZGNiNDE1ZDZkZTk2MDkxM2RiMGIwZjY3IiwidGFnIjoiIn0%3D; expires=Tue, 20 Jan 2026 04:08:22 GMT; Max-Age=31536000; path=/; secure; httponly; samesite=lax"
  ]
  "Set-Cookie" => array:2 [
    0 => "XSRF-TOKEN=eyJpdiI6IjZ2dGYrZDhDeEQwd1dwUFZTbjBDL0E9PSIsInZhbHVlIjoiRkFPQ0txbWdFTUlQdUthZS9RMXBjd2swYnI2KzhDNUlWMHRYdUpsYkdiaWdaRjBJekFTbWZhZTFSaE52SUR5TXJBVW11U2lzRnp3amZkSUtwanNVTjdFOHE3dlhqZUlTQUxlbXQwN0dzZEQ1Y0NvM0NRN01kV3lzbURpVDFpR1AiLCJtYWMiOiJjYzc3ZGQ2YTMzZDE0OGI0NDVmOTk3OGY2OTI1N2E3NzZlMWE4N2FjNWNlODc2YTY3YjI4ZTA1ZWIwYzUxZGNhIiwidGFnIjoiIn0%3D; expires=Tue, 20-Jan-2026 04:08:22 GMT; path=/; secure"
    1 => "republica_session=eyJpdiI6InIxODdqTHNlMzNXN29YQXhsRDVzbWc9PSIsInZhbHVlIjoiZW9wMUM5SWpENklYUVJWd1k4Vk5odmpMeFNMcm5mblhQYmNKS1c1d0hDTi9GUm1pbjRONnNicHBDNG4vK0ExTUg3QnJHbXZ0ZkczMTY3dlVabWRpVWtvNEVtMDVqVVRYYkFaeGE1djFkYnc4VVZkN0wyWVdmY0ZnTEJ5UmNOb24iLCJtYWMiOiI4YWY2MGQ0M2FiYjVjZWVmYjliOTZiMTYyNTY4YWUzOTk2ZjkyYzZlZGNiNDE1ZDZkZTk2MDkxM2RiMGIwZjY3IiwidGFnIjoiIn0%3D; expires=Tue, 20-Jan-2026 04:08:22 GMT; path=/; secure; httponly"
  ]
]
AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness

AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illness

Create an account, or log in
